CompaniesNectin Therapeutics
Nectin Therapeutics logo

Nectin Therapeutics

active
Jerusalem, Israel
Founded 2017
Website
About

Targeted antibodies, CAR-T and -NK drivers

Areas of Focus

Categories

Biologics & BiopharmaceuticalAntibodyMiddle East
Clinical Trials (1)
View all

Total Trials

1

As Lead Sponsor

1

As Collaborator

0

Total Enrollment

90

By Phase

PHASE1: 1

By Status

RECRUITING: 1
Clinical Trials Pipeline1 trial
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
Today
NCT05378425
Hover over trial bars to see details

Recent Trials

NCT05378425Lead Sponsor
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
PHASE1Recruiting
90 participants
Started: Sep 1, 2022 · Completed: Dec 31, 2026
Locations (1)
Headquarters
Jerusalem, Israel
Map

Loading map...